Tumor Ecosystems in B-Cell Malignancies: Identifying Immunotherapeutic Vulnerabilities

Institution: Department I of Internal Medicine and Max-Planck Institute for Biology of Ageing, University Hospital of Cologne
Applicant: PD Dr. Paul J. Bröckelmann
Funding line:
Else Kröner Excellence Fellowships

Lymphomas are a heterogeneous group of blood cancers and patients often only partially or temporarily respond to currently available immunotherapies such as CAR T-cells, checkpoint inhibitors, or bispecific antibodies. Through a high-resolution analysis of patient samples using modern sequencing and microscopy techniques, the use of innovative genetic screening methods, and various mouse models, a detailed characterization of the immune landscape and identification of potential treatment approaches are planned. The overarching goal of the research project is to identify the mechanisms underlying the response or failure of immunotherapy in lymphoma patients to ultimately develop new immunotherapeutic treatment strategies.

Here you can find further information.